OWC Pharmaceutical Research (OWC Pharmaceutical Research) Interest Expense : $-0.01 Mil (TTM As of Sep. 2019)

View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. OWC Pharmaceutical Research's interest expense for the three months ended in Sep. 2019 was $ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2019 was $-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. OWC Pharmaceutical Research's Operating Income for the three months ended in Sep. 2019 was $ -0.59 Mil. OWC Pharmaceutical Research's Interest Expense for the three months ended in Sep. 2019 was $ -0.00 Mil. OWC Pharmaceutical Research did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

OWC Pharmaceutical Research Interest Expense Historical Data

The historical data trend for OWC Pharmaceutical Research's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OWC Pharmaceutical Research Interest Expense Chart

OWC Pharmaceutical Research Annual Data

Trend

Dec08

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Interest Expense

Get a 7-Day Free Trial

-0.19

-0.01

OWC Pharmaceutical Research Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Interest Expense	Get a 7-Day Free Trial															-	-	-	-0.01	-

OWC Pharmaceutical Research Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

OWC Pharmaceutical Research (OTCPK:OWCP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

OWC Pharmaceutical Research's Interest Expense for the three months ended in Sep. 2019 was $-0.00 Mil. Its Operating Income for the three months ended in Sep. 2019 was $-0.59 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2019 was $0.02 Mil.

OWC Pharmaceutical Research's Interest Coverage for the quarter that ended in Sep. 2019 is calculated as

OWC Pharmaceutical Research did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Ben Gurion Street, Ramat Gan, ISR, 5257334

Website

http://www.owcpharma.com

OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.

Executives

Asher Zwebner

director, officer: CHIEF FINANCIAL OFFICER

CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387